Biocept, Inc. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA). Biocept offers single biomarker tests for lung, breast, melanoma, gastric, colorectal, and prostate cancers that can be used for treatment selection and response monitoring. The Company also offers tumor-specific multi-gene next-generation sequencing (NGS) panels for both lung and breast cancer. With thousands of tests performed, Biocept’s liquid biopsy platforms have demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options.
The San Diego-based company has developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells and cell-free circulating tumor DNA
Shareholders and others will have the opportunity to engage with top management from Biocept, Starton Therapeutics, Todos Medical, and Gevo